Windward Bio Lists on Nasdaq, Shares Up 68% on Debut

Windward Bio Lists on Nasdaq, Shares Up 68% on Debut

PR Newswire

Pivotal bioVenture Partners China-backed biotech built under the NewCo model on China-licensed assets debuts on Nasdaq less than two years after founding

SHANGHAI, Nov. 16, 2026 /PRNewswire/ — Windward Bio Group AG (Nasdaq: WWB), a clinical-stage biotechnology company and a portfolio company of Pivotal bioVenture Partners China, began trading on the Nasdaq Global Select Market on Nov. 13, 2026. The company priced its initial public offering at $17.00 per share and sold approximately 10.29 million ordinary shares, raising $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi. Windward closed its first day of trading with a market capitalization of approximately $1.69 billion.

Windward was founded in 2024 by serial entrepreneur Luca Santarelli, M.D., and his team, whose prior companies VectivBio and Therachon were both acquired. Since inception, the company has raised $365 million, including a $200 million Series A in January 2025 and a $165 million crossover financing in May 2026. Pivotal bioVenture Partners is among the investors that have backed Windward through every financing round since its earliest days, from formation to a Nasdaq listing in under two years.

Headquartered in Basel, Switzerland, Windward develops ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead program, WIN378, is an ultra-long-acting, fully human monoclonal antibody against thymic stromal lymphopoietin (TSLP) now advancing through POLARIS-1, a Phase 2/3 study in asthma, and SIRIUS, a Phase 2 study in COPD. Designed for twice-yearly dosing, versus the once-every-four-weeks regimen of currently approved agents, WIN378 could meaningfully ease the long-term treatment burden for patients with chronic airway disease. In September 2026, the company reported positive interim Phase 2 data supporting twice-yearly dosing of WIN378 in asthma. Windward’s pipeline also includes WIN027, a clinical-stage bispecific antibody targeting TSLP and IL-13 now in Phase 1 development.

The global rights (excluding Greater China and certain Asian markets) to both of Windward’s core programs were licensed from Chinese biopharmaceutical companies. WIN378 (HBM9378/SKB378) came out of a co-development program between Harbour BioMed and Kelun-Biotech, while WIN027 (QX027N) was licensed from Qyuns Therapeutics. Windward is the latest example of China-originated drug candidates reaching global capital markets through license-out deals.

Windward is a leading case of the NewCo model in the current wave of Chinese biotech going global: a global investment firm leads the spin-out and licensing of a Chinese company’s pipeline asset, sets up a new entity overseas, and arms it with international capital and an experienced operating team to run clinical development and commercialization worldwide — typically excluding Greater China. Pivotal bioVenture Partners China’s practice has been a consistent investor, participating in the $200 million Series A in January 2025, increasing its position in the $165 million crossover round in May 2026, and remaining a shareholder through the IPO. In less than two years, Windward has completed the full path from “China asset licensing” to “NewCo formation” to “global financing” to “IPO listing,” plugging China-originated innovation into the global value chain.

According to company disclosures, net proceeds from the offering will be used primarily for completing core clinical development of WIN378, including the Phase 2/3 and confirmatory asthma studies and the Phase 2 COPD study; advancing the global Phase 2b COPD trial and the Phase 2 atopic dermatitis trial of WIN027, the latter expected to begin enrollment in the first half of 2027; moving the bispecific program to Investigational New Drug (IND) readiness; and funding working capital and general corporate purposes. After the offering, the pipeline is expected to reach three key data milestones: top-line Phase 2 asthma data for WIN378 (POLARIS-1) in the first half of 2027, Phase 2 COPD data (SIRIUS) in the second half of 2027, and Phase 3 asthma data in the first half of 2029.

For Pivotal bioVenture Partners, Windward Bio is a prime example of the NewCo model at work — China-originated innovation matched with global capital and world-class execution. From the start, the firm saw WIN378 and WIN027 as potential best-in-class, ultra-long-acting biologics for serious respiratory and dermatologic diseases, and it has backed Luca Santarelli and his team through every financing round since formation. The Nasdaq listing in under two years — putting the value of assets originated by its Chinese partners Harbour BioMed, Kelun-Biotech and Qyuns Therapeutics on the global stage — is a milestone for Pivotal, which plans to keep supporting Windward through its next phase of growth.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep drug discovery, development and commercialization experience, focused on transforming the treatment of serious immunological diseases, including respiratory and dermatologic conditions. Its lead program, WIN378, is an ultra-long-acting anti-TSLP monoclonal antibody with best-in-class potential, now in Phase 2/3 clinical trials for asthma. The company’s pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLP×IL-13 bispecific antibody with broad therapeutic potential across inflammatory diseases, now in Phase 1. Windward is also building a long-acting bispecific antibody discovery pipeline focused on validated targets in respiratory and dermatologic diseases.

About Pivotal bioVenture Partners

Pivotal bioVenture Partners was founded by Hong Kong’s Nan Fung Group. Since launching its U.S. operations in 2017 and its China practice in 2018, Pivotal has built broad international reach and global resource-coordination capabilities. The firm seeks out innovative products and technologies worldwide, founding and investing in leading life-science companies in Greater China to meet growing medical needs in global markets — particularly China. Pivotal invests across biopharmaceuticals, medical devices and healthcare services. Its team of seasoned life-science investors and entrepreneurs brings deep industry experience in company creation and venture investment.

Contact:
Phone: +86-21-68503033
Email: info@pivotalbiovp.cn

Cision View original content:https://www.prnewswire.com/news-releases/windward-bio-lists-on-nasdaq-shares-up-68-on-debut-302940459.html

SOURCE Pivotal bioVenture Partners China